发热伴血小板减少综合征合并细菌/真菌感染诊治与防控专家共识

doi:10.3877/cma.j.issn.1674-1358.2026.02.001

发热伴血小板减少综合征（SFTS）是由发热伴血小板减少综合征病毒（SFTSV）感染引起的急性传染病，近年来发病率呈逐年上升趋势。临床实践表明，病程早期干预可显著改善患者预后，而进展为重症的患者病死率居高不下。SFTS患者合并细菌、真菌感染发生率较高，且与疾病预后密切相关，是影响临床结局的独立危险因素。为规范SFTS合并细菌/真菌感染的早期识别、诊断、治疗与防控，基于2009年本病发现以来的循证医学证据，本共识专家组联合感染、急诊、重症、检验、药学及流行病学等多学科专家，结合临床经验而制定，旨在为临床医务工作者提供科学、可操作的诊疗指导，提高SFTS合并细菌/真菌感染的综合诊治水平。

关键词: 发热伴血小板减少综合征, 合并感染, 细菌感染, 真菌感染, 专家共识

Severe fever with thrombocytopenia syndrome (SFTS) is an acute infectious disease caused by severe fever with thrombocytopenia syndrome virus (SFTSV), whose incidence has shown a year-by-year upward trend in recent years. Clinical practice has demonstrated that early intervention during the disease course can significantly improve the prognosis, whereas the mortality rate remains high in patients who progress to severe disease. Patients with SFTS have a high incidence of concurrent bacterial and fungal infections, which are closely associated with disease prognosis and constitute independent risk factors affecting clinical outcomes. To standardize the early identification, diagnosis, treatment, prevention and control of SFTS complicated with bacterial and fungal co-infections, this consensus has been formulated by an expert panel in collaboration with multidisciplinary specialists in infectious diseases, emergency medicine, critical care, laboratory medicine, pharmacy and epidemiology, based on the evidence from clinical research since the first discovery of SFTS in 2009 and combined with practical clinical experience. This consensus aims to provide the scientific and actionable guidance for clinical medical professionals and improve the comprehensive diagnosis and treatment of bacterial and fungal co-infections of patients with SFTS.

Key words: Severe fever with thrombocytopenia syndrome, Coinfection, Bacterial infection, Fungal infection, Expert consensus

[1]	Yu XJ, Liang MF, Zhang SY, et al. Fever with thrombocytopenia associated with a novel bunyavirus in China[J]. N Engl J Med,2011,364(16):1523-1532.
[2]	Liu B, Zhu J, He T, et al. Genetic variants of Dabie bandavirus: classification and biological/clinical implications[J]. Virol J,2023,20(1):68.
[3]	郑小杰, 杨鑫, 方立群, 等. 发热伴血小板减少综合征的流行病学与防控策略[J]. 中华疾病控制杂志,2025,29(3):249-253, 261.
[4]	田地, 葛子若, 张婷玉, 等. 北京市15例本土发热伴血小板减少综合征患者的临床特征[J/OL]. 中华实验和临床感染病杂志(电子版),2025,19(1):52-58.
[5]	戴艳妮, 孙袁芳, 陈秀芝, 等. 262例发热伴血小板减少综合征病例临床特征及死亡危险因素分析[J]. 安徽预防医学杂志,2025,31(2):97-102.
[6]	Liu MM, Lei XY, Yu XJ. Meta-analysis of the clinical and laboratory parameters of SFTS patients in China[J]. Virology J,2016,13(1):198.
[7]	张海滨, 刘小伟, 倪秀莹, 等. 59例老年发热伴血小板减少综合征并发多器官功能障碍患者的临床分析[J/OL]. 中华实验和临床感染病杂志(电子版),2017,11(1):69-72.
[8]	Fan Z, Lu L, Lin L, et al. Pathogen spectrum, clinical traits and exploration of mortality outcome-improving medication regimens in coinfection patients with severe fever with thrombocytopenia syndrome: a multicenter cohort study[J]. Front Cell Infect Microbiol,2025,15:1708979.
[9]	Hu YY, Xia GM, Zhang H, et al. Pathogen profile of co-infections and mortality determinants among patients with severe fever with thrombocytopenia syndrome[J]. Front Cell Infect Microbiol,2025,15:1693567.
[10]	Song L, Zhao Y, Wang G, et al. Investigation of predictors for invasive pulmonary aspergillosis in patients with severe fever with thrombocytopenia syndrome[J]. Sci Rep,2023,13(1):1538.
[11]	Seo JW, Kim D, Yun N, et al. Clinical update of severe fever with thrombocytopenia syndrome[J]. Viruses,2021,13(7):1213.
[12]	Wang H, Luo M, Fisher D, et al. Clinical factors associated with invasive pulmonary aspergillosis in patients with severe fever with thrombocytopenia syndrome: analysis of a 6-year clinical experience[J]. Front Microbiol,2024,15:1448710.
[13]	Kim EH, Jang HB, Kim SM, et al. Age-associated immune dysregulation and B cell dysfunction drive severe outcomes in SFTSV infection[J]. PLoS pathogens,2025,21(8):e1013402.
[14]	Zuo Y, Wang H, Huang J, et al. Pulmonary infection in patients with severe fever with thrombocytopenia syndrome: A multicentre observational study[J]. J Med Virol,2023,95(4):e28712.
[15]	Zhang Y, Huang Y, Xu Y. Associated microbiota and treatment of severe fever with thrombocytopenia syndrome complicated with infections[J]. J Med Virol,2022,94(12):5916-5921.
[16]	Iwao K, Kawaguchi T, Kimura M, et al. Severe fever with thrombocytopenia syndrome accompanied by invasive pulmonary aspergillosis: An autopsy case[J]. Viruses,2021,13(6):1086.
[17]	Xu Y, Shao M, Liu N, et al. Invasive pulmonary aspergillosis is a frequent complication in patients with severe fever with thrombocytopenia syndrome: A retrospective study[J]. Int J Infect Dis,2021,105:646-652.
[18]	Song H, Zou S, Huang Y, et al. The pathogenic and clinical characteristics of severe fever with thrombocytopenia syndrome patients with co-infections[J]. Front Cell Infect Microbiol,2023,13:1298050.
[19]	Song L, Zhao Y, Wang G, et al. Investigation of predictors for invasive pulmonary aspergillosis in patients with severe fever with thrombocytopenia syndrome[J]. Sci Rep,2023,13(1):1538.
[20]	Ge HH, Wang G, Guo PJ, et al. Coinfections in hospitalized patients with severe fever with thrombocytopenia syndrome: A retrospective study[J]. J Med Virol,2022,94(12):5933-5942.
[21]	Hu YY, Xia GM, Zhang H, et al. Pathogen profile of co-infections and mortality determinants among patients with severe fever with thrombocytopenia syndrome[J]. Front Cell Infect Microbiol,2025,15:1693567.
[22]	Park SW, Lee CS, Kim JH, et al. Severe fever with thrombocytopenia syndrome: comparison with scrub typhus and clinical diagnostic prediction[J]. BMC Infect Dis,2019,19(1):174.
[23]	Wang H, Luo M, Fisher D, et al. Clinical factors associated with invasive pulmonary aspergillosis in patients with severe fever with thrombocytopenia syndrome: analysis of a 6-year clinical experience[J]. Front Microbiol,2024,15:1448710.
[24]	Hu L, Kong Q, Yue C, et al. Early-warning immune predictors for invasive pulmonary aspergillosis in severe patients with severe fever with thrombocytopenia syndrome[J]. Front Immunol,2021,12:576640.
[25]	Lee H, Choi WY, Kim CM, et al. A case of SFTS coinfected with E. coli bacteremia[J]. BMC Infect Dis,2021,21(1):25.
[26]	王宁, 张伟, 段建平, 等. 发热伴血小板减少综合征神经系统受累患者的临床特征[J]. 中国感染控制杂志,2018,17(11):958-964.
[27]	Dai Y, Pu Q, Hu N, et al. The dose-response relationship between smoking and the risk factor for invasive pulmonary aspergillosis in patients with severe fever with thrombocytopenia syndrome[J]. Front Microbiol,2023,14:1209705.
[28]	Akagi K, Miyazaki T, Oshima K, et al. Detection of viral RNA in diverse body fluids in an SFTS patient with encephalopathy, gastrointestinal bleeding and pneumonia: a case report and literature review[J]. BMC Infect Dis,2020,20(1):281.
[29]	康红, 王小利, 杨鑫, 等. 宏基因组二代测序技术在感染性疾病诊断中的应用[J]. 山西医药杂志,2024,53(5):369-375.
[30]	国家卫生健康委办公厅, 国家中医药局综合司. 发热伴血小板减少综合征诊疗方案(2023年版)[J]. 中国感染控制杂志,2024,23(7):918-920.
[31]	Lu QB, Li H, Jiang FC, et al. The differential characteristics between severe fever with thrombocytopenia syndrome and hemorrhagic fever with renal syndrome in the endemic regions[J]. Open Forum Infect Dis,2019,6(12):ofz477.
[32]	Seo JW, Lee YM, Tamanna S, et al. Analysis of changes in viral load and inflammatory cytokines, as well as the occurrence of secondary infections, in SFTS patients treated with specific treatments: A prospective multicenter cohort study[J]. Viruses,2024,16(12):1906.
[33]	Woo D, Michelow IC, Choi Y, et al. Transmission of severe fever with thrombocytopenia syndrome (SFTS) to humans: A systematic review of individual participant data and meta-analysis[J]. J Infect Public Health,2025,18(6):102685.
[34]	Song L, Zou W, Wang G, et al. Cytokines and lymphocyte subsets are associated with disease severity of severe fever with thrombocytopenia syndrome[J]. Virol J,2024,21(1):126.
[35]	Xiao W, Zhang L, Cao C, et al. Development and validation of a clinical and laboratory-based nomogram to predict mortality in patients with severe fever with thrombocytopenia syndrome[J]. BMC Infect Dis,2024,24(1):1206.
[36]	Qiu PP, Cai SJ, Guo LL, et al. Elevated CD4^-CD8^- double-negative T cells in the peripheral blood of SFTS patients are associated with disease severity[J]. Clin Chim Acta,2025,574:120312.
[37]	Huang D, Song L, Zou W, et al. Evaluation of the efficacy of prophylactic use of voriconazole against invasive pulmonary aspergillosis among severe fever with thrombocytopenia syndrome patients in China[J]. J Med Virol,2025,97(7):e70500.
[38]	Singh S, Singh M, Verma N, et al. Comparative accuracy of 1, 3 beta-D glucan and galactomannan for diagnosis of invasive fungal infections in pediatric patients: a systematic review with meta-analysis[J]. Med Mycol,2021,59(2):139-148.
[39]	Li J, Li S, Yang L, et al. Severe fever with thrombocytopenia syndrome virus: a highly lethal bunyavirus[J]. Crit Rev Microbiol,2021,47(1):112-125.
[40]	闫文月, 李强. 发热伴血小板减少综合征与肾综合征出血热的诊断与鉴别诊断的研究进展[J]. 上海交通大学学报(医学版),2023,43(11):1457-1462.
[41]	Wang Y, Song Z, Wei X, et al. Clinical laboratory parameters and fatality of Severe fever with thrombocytopenia syndrome patients: A systematic review and meta-analysis[J]. PLoS Negl Trop Dis,2022,16(6):e0010489.
[42]	Zhang M, Du Y, Yang L, et al. Development of monoclonal antibody based IgG and IgM ELISA for diagnosis of severe fever with thrombocytopenia syndrome virus infection[J]. Braz J Infect Dis,2022,26(4):102386.
[43]	Zhan L, Huang K, Xia W, et al. The diagnosis of severe fever with thrombocytopenia syndrome using metagenomic next-generation sequencing: case report and literature review[J]. Infect Drug Resist,2022,15:83-89.
[44]	Xu N, Wen S, Yao Y, et al. Two-transcript signature for differentiation and clinical outcomes in severe fever with thrombocytopenia syndrome (SFTS) patients: a double-blind, multicenter, validation study[J]. J Clin Microbiol,2025,63(1):e0128224.
[45]	Graci JD, Cameron CE. Mechanisms of action of ribavirin against distinct viruses[J]. Rev Med Virol,2006,16(1):37-48.
[46]	姚文思, 葛鸿翰, 周超, 等. 发热伴血小板减少综合征患者多药耐药菌感染及其耐药性[J]. 中华医院感染学杂志,2022,32(24):3736-3741.
[47]	Li H, Zhang LK, Li SF, et al. Calcium channel blockers reduce severe fever withthrombocytopenia syndrome virus (SFTSV) related fatality[J]. Cell Res,2019,29(9):739-753.
[48]	Boretti A, Banik B. Antibiotic resistance: revisiting older antibiotics for modern bacterial challenges[J]. Chem Biodivers,2025,22(10):e00813.
[49]	Wang G, Liu P, Xie H, et al. Impact of glucocorticoid therapy on 28-day mortality in patients having severe fever with thrombocytopenia syndrome in an intensive care unit: A retrospective analysis[J]. J Inflamm Res,2024,17:7627-7637.
[50]	Wang X, Liu Y, Zhang Y, et al. Associated microbiota and treatment of severe fever with thrombocytopenia syndrome complicated with infections[J]. J Med Virol,2022,94(10):4598-4607.
[51]	于翠香, 王西艳. 《中国成人医院获得性肺炎与呼吸机相关性肺炎诊断和治疗指南(2018年版)》解读[J]. 中国医刊,2021,56(9):951-953.
[52]	Chen X, Yu Z, Qian Y, et al. Clinical features of fatal severe fever with thrombocytopenia syndrome that is complicated by invasive pulmonary aspergillosis[J]. J Infect Chemother,2018,24(6):422-427.
[53]	赖建明, 段建平, 陈鹏, 等. 发热伴血小板减少综合征合并真菌感染患者的临床特征与危险因素分析[J]. 精准医学杂志,2021,36(2):185-188.
[54]	Bae S, Hwang HJ, Kim MY, et al. Invasive pulmonary aspergillosis in patients with severe fever with thrombocytopenia syndrome[J]. Clin Infect Dis,2020,70(7):1491-1494.
[55]	Kato H, Yamagishi T, Shimada T, et al. Epidemiological and clinical features of severe fever with thrombocytopenia syndrome in Japan, 2013-2014[J]. PLoS One,2016,11(10):e0165207.
[56]	Chen Y, Wang H, Zhou F, et al. The use of glucocorticoid in severe fever with thrombocytopenia syndrome: a retrospective cohort study[J]. Front Cell Infect Microbiol,2024,14:1419015.
[57]	Kawaguchi T, Umekita K, Yamanaka A, et al. Corticosteroids may have negative effects on the management of patients with severe fever with thrombocytopenia syndrome: a case-control study[J]. Viruses,2021,13(5):796.
[58]	De Clercq E, Li G. Approved antiviral drugs over the past 50 years[J]. Clin Microbiol Rev,2016,29(3):695-747.
[59]	Nakamura S, Azuma M, Maruhashi T, et al. Steroid pulse thera py in patients with encephalopathy associated with severe fever with thrombocytopenia syndrome[J]. J Infect Chemother,2018,24(5):389-392.
[60]	Yoo JR, Kim SH, Kim YR, et al. Application of therapeutic plas ma exchange in patients having severe fever with thrombocyto penia syndrome[J]. Korean J Intern Med,2019,34(4):902-909.
[61]	Saijo M. Pathophysiology of severe fever with thrombocytopenia syndrome and development of specific antiviral therapy[J]. J In fect Chemother,2018,24(10):773-781.
[62]	夏鹏, 蒋陈晓, 颜霄迪, 等. 糖皮质激素在发热伴血小板减少综合征患者中的应用进展[J]. 药学与临床研究,2024,32(4):349-354.
[63]	Jin C, Liang M, Ning J, et al. Pathogenesis of emerging severe fever with thrombocytopenia syndrome virus in C57/BL6 mouse model[J]. Proc Natl Acad Sci USA,2012,109(25):10053-10058.
[64]	Jin C, Jiang H, Liang M, et al. SFTS virus infection in nonhuman primates[J]. J Infect Dis,2015,211(6):915-925.
[65]	Gowen BB, Hickerson BT. Hemorrhagic fever of bunyavirus etiology:disease models and progress towards new therapies[J]. J Microbiol,2017,55(3):183-195.
[66]	Dou L, Tao X, Zhao W, et al. shRNAtargetingnonstructuralproteininhibits thereplicationof severe feverwith thrombocytopeniasyn dromevirus[J]. Future Virol,2021,16(7):451-458.
[67]	Kim J, Park S, Lee J, et al. Prediction of mortality by clinical laboratory parameters in severe fever with thrombocytopenia syndrome[J]. J Clin Med,2024,13(2):382.
[68]	Zhang Q, Sun L, Wang H, et al. Serum mAST/ALT ratio had high predictive value for adverse outcome of severe fever with thrombocytopenia syndrome with severe condition[J]. BMC Infect Dis,2023,23(1):712.
[69]	Song L, Zhao Y, Wang G, et al. nia syndrome patients from 2015 to 2019 in Shandong, China[J]. Eur J Clin Microbiol Infect Dis,2022,41(12):1415-1420.
[70]	Li MM, Zhang WJ, Weng XF, et al. CD4 T cell loss and Th2 and Th17 bias are associated with the severity of severe fever with thrombocytopenia syndrome (SFTS)[J]. Clin Immunol,2018,195:8-17.
[71]	Nakamura S, Azuma M, Maruhashi T, et al. Steroid pulse therapy in patients withencephalopathy associated with severe fever with thrombocytopenia syndrome[J]. J Infect Chem,2018,24(5):389-392.
[72]	Zhang Y, Liu X, Zhao J, et al. Pathogen profile and mortality determinants of coinfections in patients with severe fever with thrombocytopenia syndrome[J]. Emerg Microbes Infect,2024,13(1):2324321.
[73]	Yoo JR, Kim SH, Kim YR, et al. Application of therapeutic plasma exchange inpatients having severe fever with thrombocytopenia syndrome[J]. Korean J Intern Med,2019,34(4):902-909.
[74]	Perfect JR, Dismukes WE, Dromer F, et al. Clinical practice guidelines for the management of cryptococcal disease: 2010 update by the infectious diseases society of america[J]. Clin Infect Dis,2010,50(3):291-322.
[75]	Pappas PG, Kauffman CA, Andes DR, et al. Clinical practice guideline for the management of Candidiasis: 2016 update by the infectious diseases society of America[J]. Clin Infect Dis,2016,63(4):e1-e60.
[76]	Kim KH, Kim J, Ko M, et al. An anti-Gn glycoprotein antibody from aconvalescent patient potently inhibits the infection of severe fever withthrombocytopenia syndrome virus[J]. PLoS Pathogens,2019,15(2):e1007375.
[77]	Li A, Dai X, Chen L, et al. Immunogenicity and protective efficacy of aninactivated SFTS vaccine candidate in mice[J]. Biosaf Health,2022,4(1):45-52.
[78]	Kwak JE, Kim YI, Park SJ, et al. Development of a SFTSV DNA vaccine thatconfers complete protection against lethal infection in ferrets[J]. Nat Commun,2019,10(1):3836.
[79]	孙娜, 陈志海. 发热伴血小板减少综合征患者的血液及免疫系统损伤[J/OL]. 中华实验和临床感染病杂志(电子版),2018,12(6):538-542.
[80]	Zhang T, Xu Y, Ge Z, et al. Geriatric nutritional risk index plays important role in predicting in-hospital mortality in patients with severe fever with thrombocytopenia syndrome: A multi-center observational study[J]. J Med Virol,2025,97(2):e70252.
[81]	中国中西医结合学会传染病专业委员会. 发热伴血小板减少综合征中西医结合诊疗专家共识[J]. 环球中医药,2019,12(10):1506-1511.
[82]	李俊, 曾瑞峰, 奚小土, 等. 急性虚证与合并细菌/真菌感染[J]. 中国中西医结合急救杂志,2015,22(3):225-226.
[83]	周伟, 张伟, 王汝刚, 等. 人感染新型布尼亚病毒病中医临床特征分析[J]. 国际医药卫生导报,2019,25(8):1268-1270.
[84]	李建生, 王至婉, 余学庆. 中医外治法在感染性疾病中调节免疫的研究进展[J]. 中华中医药学刊,2025,43(2):12-18.
[85]	赵刚, 李丽. 电针足三里, 关元和气海穴位通过PD-1通路调节脓毒症患者的免疫功能[J]. 中华麻醉学杂志,2023,43(1):78-83.
[86]	世界中医药学会联合会急诊专业委员会, 中华中医药学会急诊专业委员会, 中国急诊专科医联体, 等. 重症多重耐药菌感染中西医诊疗专家共识[J]. 中国中医急症,2023,32(4):565-570.
[87]	中国中西医结合学会急救医学专业委员会, 《中国中西医结合急救杂志》编辑委员会. 脓毒性休克中西医结合诊治专家共识[J]. 中华危重病急救医学,2019,31(11):1317-1323.
[88]	Kim D, Lai CJ, Cha I, et al. Current progress of severe fever with thrombocytopenia syndrome virus (SFTSV) vaccine development[J]. Viruses,2024,16(1):128.
[89]	中华人民共和国国家卫生健康委员会. 医疗机构重点部门感染预防与控制通用标准: WS/T 860-2025[S]. 北京: 中国标准出版社,2025.
[90]	中华人民共和国国家卫生和计划生育委员会. 医院消毒供应中心第2部分: 清洗消毒及灭菌技术操作规范: WS 310. 2-2016[S]. 北京: 中国标准出版社,2016.

[1]	中国临床肿瘤学会乳腺癌专家委员会, 中国医师协会肿瘤多学科诊疗专业委员会, 广东省药学会. 乳腺癌内分泌治疗超说明书用药专家共识[J/OL]. 中华乳腺病杂志(电子版), 2026, 20(02): 69-81.
[2]	中华医学会超声医学分会, 中国研究型医院肿瘤介入治疗委员会, 中国妇幼保健协会乳腺保健专业委员会, 中华医学会肿瘤学分会乳腺癌专业委员会, 中国抗癌协会乳腺癌专业委员会, 中国人体健康科技促进会乳腺专业委员会. 无手术适应证乳腺癌消融治疗专家共识（2025版）[J/OL]. 中华乳腺病杂志(电子版), 2026, 20(01): 1-8.
[3]	王闪, 张忠威, 邓莉平, 熊勇, 高世成, 梁科, 张永喜, 马智勇. 发热伴血小板减少综合征与恙虫病临床特征对比分析：基于单中心真实世界的诊疗启示[J/OL]. 中华实验和临床感染病杂志(电子版), 2026, 20(01): 15-21.
[4]	中国肝移植注册中心, 国家肝脏移植质控中心, 国家人体捐献器官获取质控中心, 中国医师协会器官移植医师分会移植器官质量控制专业委员会, 国家创伤医学中心器官保护专业委员会, 中国器官移植发展基金会. 中国器官移植AI辅助临床决策专家共识[J/OL]. 中华移植杂志(电子版), 2026, 20(01): 27-37.
[5]	泌尿功能障碍预防和治疗专家组. 尿液菌群移植在部分女性泌尿系统疾病中的应用规范专家共识[J/OL]. 中华腔镜泌尿外科杂志(电子版), 2026, 20(02): 127-133.
[6]	高文娟, 张婷婷, 资仪, 张梦霞. 急性加重期慢性阻塞性肺疾病继发院内肺部真菌感染诊疗措施的研究进展[J/OL]. 中华肺部疾病杂志(电子版), 2026, 19(02): 326-329.
[7]	中国研究型医院学会微创外科学专业委员会, 中国研究型医院学会智能医学专业委员会. 肝切除日归手术多学科专家共识(2026版)[J/OL]. 中华腔镜外科杂志(电子版), 2026, 19(02): 65-76.
[8]	中国研究型医院学会微创外科学专业委员会. 胆道残余结石诊疗中国专家共识(2026版)[J/OL]. 中华腔镜外科杂志(电子版), 2026, 19(01): 1-8.
[9]	中国医师协会结直肠肿瘤专业委员会单孔腹腔镜学组. 单孔腹腔镜结直肠手术专家共识（2025版）[J/OL]. 中华结直肠疾病电子杂志, 2026, 15(02): 97-103.
[10]	中国医师协会结直肠肿瘤专业委员会, 中国抗癌协会NOSES专业委员会, 中国NOSES联盟. 结肠镜辅助结肠肿瘤经自然腔道取标本手术专家共识及操作标准[J/OL]. 中华结直肠疾病电子杂志, 2026, 15(02): 104-114.
[11]	脊髓电刺激治疗卒中后偏瘫中国专家共识编写组, 中华医学会神经外科学分会功能神经外科学组, 中国研究型医院学会神经外科学专业委员会, 世界华人神经外科协会功能神经外科专业委员会, 北京医学会神经外科学分会功能神经外科专业组, 北京医学会神经外科学分会周围神经外科专业组. 脊髓电刺激治疗卒中后偏瘫中国专家共识（2025年）[J/OL]. 中华脑科疾病与康复杂志(电子版), 2026, 16(01): 8-18.
[12]	陈秀梅, 谢曼英, 陈思涓, 钟旭辉, 潘巧, 温丽娟, 本共识编写小组. 晚期非小细胞肺癌患者免疫相关不良反应的护理专家共识[J/OL]. 中华临床医师杂志(电子版), 2026, 20(02): 77-89.
[13]	中国医师协会介入医师分会外周血管专家工作委员会. 支气管动脉栓塞治疗咯血护理规范专家共识[J/OL]. 中华介入放射学电子杂志, 2026, 14(01): 1-11.
[14]	中华医学会检验医学分会分子诊断学组, 中华医学会检验医学分会临床免疫学组, 中国民族卫生协会流式细胞技术临床应用推广组. 医疗机构临床流式细胞实验室建设专家共识[J/OL]. 中华临床实验室管理电子杂志, 2026, 14(02): 89-103.
[15]	中华医学会心电生理和起搏分会, 中国医学装备协会心律失常技术分会, 中国医师协会心律学专业委员会. 心血管植入型电子器械磁共振成像检查标准流程建议[J/OL]. 中华心脏与心律电子杂志, 2026, 14(01): 1-10.

阅读次数

全文

摘要

选择文件类型/文献管理软件名称

选择包含的内容

Expert consensus on diagnosis, treatment, prevention and control of severe fever with thrombocytopenia syndrome complicated with bacterial/fungal infection

模态框（Modal）标题

选择文件类型/文献管理软件名称

选择包含的内容

Expert consensus on diagnosis, treatment, prevention and control of severe fever with thrombocytopenia syndrome complicated with bacterial/fungal infection